{
    "clinical_study": {
        "@rank": "65527", 
        "arm_group": [
            {
                "arm_group_label": "Synbiotic", 
                "arm_group_type": "Active Comparator", 
                "description": "Each synbiotic capsule (Protexin, UK) contained 2 \u00d7 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "250 mg Maltodexterin"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effects of synbiotic supplementation on insulin resistance, and lipid\n      profile in subjects with metabolic syndrome, in a randomized, double-blind,\n      placebo-controlled pilot study, 38 subjects with metabolic syndrome will be supplemented\n      with either synbiotic or placebo capsules twice/day for 28 weeks. Both the synbiotic (G1)\n      and the placebo (G2) groups will be advised to follow an energy balanced diet and physical\n      activity recommendations. Parameters related to metabolic syndrome and insulin resistance\n      will be measured every 7 weeks during the study course."
        }, 
        "brief_title": "Effects of Synbiotic Supplementation in Metabolic Syndrome", 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age and older\n\n          -  having three of the following five features: Increased waist circumference (\u2265102 cm\n             in men and \u226588 cm in women), elevated TG (\u2265150 mg/dl), reduced HDL-C (\u226440 mg/dl in\n             men and \u226450 mg/dl in women), elevated blood pressure (\u2265130/85 mm Hg or on treatment\n             for hypertension) and elevated glucose (\u2265100 mg/dl), according to the National\n             Cholesterol Education Program Adult Treatment Panel III report\n\n          -  BMI :  25\u2265  BMI \u2265 40\n\n        Exclusion Criteria:\n\n          -  Use antibiotic 2 weeks before recruitment to the study\n\n          -  A history of alcohol consumption\n\n          -  Pregnancy & Breast feeding , Professional athelets\n\n          -  A history of Cardiovascular disease, Pulmonary disease, Renal disease & Celiac\n             disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008838", 
            "org_study_id": "450"
        }, 
        "intervention": [
            {
                "arm_group_label": "Synbiotic", 
                "intervention_name": "Synbiotic", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 10, 2013", 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "HOMA-IR", 
            "safety_issue": "No", 
            "time_frame": "28 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008838"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Nutrition and Food Technology Institute", 
            "investigator_full_name": "Dr Azita Hekmatdoost", 
            "investigator_title": "Assisstant Prof", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "National Nutrition and Food Technology Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Nutrition and Food Technology Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}